Abstract
Background: Breast cancer is one of the high prevalence cancers worldwide affecting women based on various factors. Hormonal changes are amongst the factors involved in the development of breast cancer. The basic hormones involved include estrogen and progesterone with human epidermal receptor-2 (HER2) which could be either over expressed or not at all expressed. Therefore, studies were conducted on the DMBA induced breast cancer model.
Methods: As per literature review, there has been complete befuddlement on the hormonal crisis of the DMBA induced model hence we performed the immunohistochemistry studies of estrogen, progesterone and human epidermal receptor-2 in order to prove the presence or absence of the major hormones involved in progression of breast cancer. Preceding morphological tumor detection, it was further confirmed with hematoxylineosin stained sections. Results: These data initially detected the probable presence of mucin in the hematoxylin- eosin stain hence we performed specific mucin stain using Meyer’s mucincarmine concluding mucinous carcinoma. Thereafter, we obtained negative estrogen and HER2, with positive progesterone in the immunohistochemistry studies. Conclusion: Conclusively, DMBA induced breast cancer is a suitable model for mucinous carcinoma in estrogen and human epidermal receptor-2 negative and progesterone positive breast cancer.Keywords: Breast cancer, DMBA, Estrogen, Progesterone, HER-2, DNA, carcinomace.
Current Cancer Therapy Reviews
Title:DMBA- Induced Breast Cancer: A Hormonal Camouflage
Volume: 12 Issue: 4
Author(s): Anita K. Bakrania, Bhavesh C. Variya and Snehal S. Patel*
Affiliation:
- Department of Pharmacology, Institute of Pharmacy, Nirma University, Ahmedabad, Gujarat, 382 481,India
Keywords: Breast cancer, DMBA, Estrogen, Progesterone, HER-2, DNA, carcinomace.
Abstract: Background: Breast cancer is one of the high prevalence cancers worldwide affecting women based on various factors. Hormonal changes are amongst the factors involved in the development of breast cancer. The basic hormones involved include estrogen and progesterone with human epidermal receptor-2 (HER2) which could be either over expressed or not at all expressed. Therefore, studies were conducted on the DMBA induced breast cancer model.
Methods: As per literature review, there has been complete befuddlement on the hormonal crisis of the DMBA induced model hence we performed the immunohistochemistry studies of estrogen, progesterone and human epidermal receptor-2 in order to prove the presence or absence of the major hormones involved in progression of breast cancer. Preceding morphological tumor detection, it was further confirmed with hematoxylineosin stained sections. Results: These data initially detected the probable presence of mucin in the hematoxylin- eosin stain hence we performed specific mucin stain using Meyer’s mucincarmine concluding mucinous carcinoma. Thereafter, we obtained negative estrogen and HER2, with positive progesterone in the immunohistochemistry studies. Conclusion: Conclusively, DMBA induced breast cancer is a suitable model for mucinous carcinoma in estrogen and human epidermal receptor-2 negative and progesterone positive breast cancer.Export Options
About this article
Cite this article as:
Bakrania K. Anita , Variya C. Bhavesh and Patel S. Snehal *, DMBA- Induced Breast Cancer: A Hormonal Camouflage, Current Cancer Therapy Reviews 2016; 12 (4) . https://dx.doi.org/10.2174/1573394713666170316124720
DOI https://dx.doi.org/10.2174/1573394713666170316124720 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics
The thematic issue will focus on key areas such as lipid nanoparticles, mRNA therapeutics, drug delivery systems, nanotechnology in medicine, targeted therapy, non-viral vectors, precision medicine, and biomedical engineering.read more
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Meet Our Editorial Board Member:
Current Cancer Drug Targets Multifunctional Hydroxyapatite-based Nanoparticles for Biomedicine: Recent Progress in Drug Delivery and Local Controlled Release
Current Mechanics and Advanced Materials Resilience Dysregulation in Major Depressive Disorder: Focus on Glutamatergic Imbalance and Microglial Activation
Current Neuropharmacology Subject Index To Volume 1
Current Gene Therapy Pioglitazone and Cancer: Angel or Demon?
Current Pharmaceutical Design Updates on the Production of Therapeutic Antibodies Using Human Hybridoma Technique
Current Pharmaceutical Design Patent Selections
Recent Patents on DNA & Gene Sequences Current Advances and Prospects in Carbon Nanomaterials-based Drug Deliver Systems for Cancer Therapy
Current Medicinal Chemistry Emerging Technologies, Recent Developments, and Novel Applications for Drug Metabolite Identification
Current Drug Metabolism The Role of the Adenosinergic Pathway in Immunosuppression Mediated by Human Regulatory T Cells (Treg)
Current Medicinal Chemistry Anticipation in Lynch Syndrome: Where We Are Where We Go
Current Genomics 3D-QSAR and Docking Studies on Pyrimidine Derivatives as CSF-1R Inhibitors
Letters in Drug Design & Discovery Micro-Nanomaterials for Tumor Microwave Hyperthermia: Design, Preparation, and Application
Current Drug Delivery Control of Copper Status for Cancer Therapy
Current Cancer Drug Targets Radiolabeled Glucose Derivatives for Tumor Imaging Using SPECT and PET
Current Medicinal Chemistry S100A8/A9 Proteins in Diseases of the Exocrine Pancreas
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Applications of Nanomaterials for Cancer Treatment: Recent Patents Review
Recent Patents on Nanomedicine Lipid based Nanocapsules: A Multitude of Biomedical Applications
Current Pharmaceutical Biotechnology Manganese Superoxide Dismutase (Sod2) and Redox-Control of Signaling Events That Drive Metastasis
Anti-Cancer Agents in Medicinal Chemistry Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as Therapeutics: Rationales, Controversies, Clinical Experience
Current Drug Targets